-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Entrada Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2020 to Q2 2024.
- Entrada Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was $53.4M.
- Entrada Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was $93.5M.
- Entrada Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$3.16M, a 96.7% increase from 2022.
- Entrada Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$97.2M, a 90.2% decline from 2021.
- Entrada Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$51.1M, a 91.7% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)